Virax Biolabs to Consolidate Shares 1-for-25 on June 26 to Meet Nasdaq $1 Rule
VRAX•Virax Biolabs will consolidate its shares 1-for-25 effective June 26, 2026, with trading under the VRAX symbol and new CUSIP G9495L133 to regain compliance with Nasdaq’s $1 minimum bid requirement. Every 25 US$0.001 shares will become one US$0.025 share, with fractional amounts rounded up and shareholder percentages unchanged.
1. Share Consolidation Details
The board approved a 1-for-25 share consolidation effective June 26, 2026, converting every twenty-five US$0.001 par value shares into one US$0.025 share. No fractional shares will be issued; resulting fractional interests will be rounded up to the nearest whole share.
2. Nasdaq Compliance Objective
The consolidation is intended to elevate the per-share price above Nasdaq Capital Market’s $1 minimum bid requirement and maintain the company’s listing under ticker VRAX. Post-consolidation trading will occur under the same symbol with a new CUSIP G9495L133, and shareholder ownership percentages remain unchanged except for rounding.
